What is Buserelin?

A GnRH analog (Suprefact) given by nasal spray or injection, used in prostate cancer and fertility treatment.

Buserelin in the library · · Human Trials · What are peptides?

24 registered trials · 387 indexed papers · 421 human / 27 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

Type: GnRH analog peptide.

Definition (National Library of Medicine)

“A potent synthetic analog of gonadotropin-releasing hormone with D-serine substitution at residue 6, glycine10 deletion, and other modifications.”

MeSH: Buserelin

Human research

The registered human trials and peer-reviewed human studies linked below are listed from ClinicalTrials.gov and PubMed. A study is linked only when Buserelin is one of its interventions, or is named in the study title or subject headings.

Listing a study does not mean it showed a benefit, and it is not medical advice.

Registered human trials (24)

Trial	Phase	Status	Year	Enrolled
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial	Phase 3	active not recruiting	2021	2753
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial	Phase 3	active not recruiting	2021	2050
Co Administration of GnRH Agonist and hCG for Final Oocyte Maturation	Phase 4	completed	2016	276
Efficacy of Ovarian Stimulation Based on FSHR Genotype Status	Phase 3	suspended	2015	165
Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer	Phase 1	terminated	2014	6
Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles	Phase 4	terminated	2013	194
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer	Phase 3	recruiting	2012	192
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer	Phase 3	completed	2012	239
The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol	Phase 3	unknown	2012	200
Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist	Phase 4	completed	2010	120
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer	Phase 3	completed	2009	1538
Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles	Phase 4	completed	2009	384
Mild Stimulation Protocol Versus Microdose Gonadotropin-releasing Hormone Agonist Flare up Protocol in Poor Responders	Phase 4	completed	2009	159
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer	Phase 3	unknown	2008	1792
Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer	Phase 3	terminated	2008	48
Antagonist/Letrozole in Poor Responders	Phase 1/Phase 2	completed	2008	120
Replacement of Fresh Embryo Transfers (ETs) by Frozen Embryo Transfers (FETs) Using Vitrification	Phase 1/Phase 2	unknown	2008	500
Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist	Phase 4	completed	2008	200
Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH	Phase 3	unknown	2008	2
Half-Dose Depot Triptorelin Versus Reduced-Dose Daily Buserelin	Phase 4	completed	2005	182
Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy	Phase 3	unknown	2004	400
Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer	Phase 1	completed	2002	25
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer	Phase 3	completed	1999	1386
Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer	Phase 3	completed	1995	361

Peer-reviewed studies (387)

Paper	Authors	Journal	Year	Type
The influence of serum luteinising hormone concentrations post GnRH agonist trigger on metaphase II oocytes in IVF/ICSI cycles	Sawant S et al.	European journal of obstetrics, gynecology, and reproductive biology	2025	Observational Study
Response to ovulation trigger is correlated to late follicular phase progesterone levels: A hypothesis explaining reduced reproductive outcomes caused by increased late follicular progesterone rise	Friis Wang N et al.	Human reproduction (Oxford, England)	2019	Randomized Controlled Trial
The impact of HCG in IVF Treatment: Does it depend on age or on protocol?	Theofanakis C et al.	Journal of gynecology obstetrics and human reproduction	2019	Randomized Controlled Trial
Addition of low-dose hCG to rFSH during ovarian stimulation for IVF/ICSI: is it beneficial?	Partsinevelos GA et al.	Clinical and experimental obstetrics & gynecology	2016	Clinical Study
Treatment with hCG 4 or 6 days after TAI to improve pregnancy outcomes in repeat-breeding dairy cows	Alnimer MA et al.	Animal reproduction science	2015	Randomized Controlled Trial
Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort	Höfner T et al.	World journal of urology	2015	Observational Study
Comparison of gene expression profiles in granulosa and cumulus cells after ovulation induction with either human chorionic gonadotropin or a gonadotropin-releasing hormone agonist trigger	Borgbo T et al.	Fertility and sterility	2013	Randomized Controlled Trial
An investigational ovarian stimulation protocol increased significantly the psychological burden in women with premature ovarian failure	Awwad JT et al.	Acta obstetricia et gynecologica Scandinavica	2012	Clinical Trial
GnRH-agonist versus GnRH-antagonist IVF cycles: is the reproductive outcome affected by the incidence of progesterone elevation on the day of HCG triggering? A randomized prospective study	Papanikolaou EG et al.	Human reproduction (Oxford, England)	2012	Randomized Controlled Trial
Hyperinsulinemia amplifies GnRH agonist stimulated ovarian steroid secretion in women with polycystic ovary syndrome	Tosi F et al.	The Journal of clinical endocrinology and metabolism	2012	Controlled Clinical Trial
IVM is an alternative for patients with PCO after failed conventional IVF attempt	Gulekli B et al.	Journal of assisted reproduction and genetics	2011	Clinical Trial
Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain	Kitawaki J et al.	European journal of obstetrics, gynecology, and reproductive biology	2011	Clinical Trial
Comparison of mild and microdose GnRH agonist flare protocols on IVF outcome in poor responders	Karimzadeh MA et al.	Archives of gynecology and obstetrics	2011	Randomized Controlled Trial
Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy	Langenhuijsen JF et al.	Urologic oncology	2011	Clinical Trial, Phase II
Comparison of gonadotropin-releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients	Hosseini MA et al.	The journal of obstetrics and gynaecology research	2010	Randomized Controlled Trial
Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients	Tehraninejad ES et al.	Archives of gynecology and obstetrics	2010	Randomized Controlled Trial
Large prospective, pregnancy and infant follow-up trial assures the health of 1000 fetuses conceived after treatment with the GnRH antagonist ganirelix during controlled ovarian stimulation	Bonduelle M et al.	Human reproduction (Oxford, England)	2010	Clinical Trial
A randomised controlled trial of 300 versus [amount hidden] recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count	Jayaprakasan K et al.	BJOG : an international journal of obstetrics and gynaecology	2010	Randomized Controlled Trial
Comparing GnRH agonist long protocol and GnRH antagonist protocol in outcome the first cycle of ART	Firouzabadi RD et al.	Archives of gynecology and obstetrics	2010	Randomized Controlled Trial
[Somatostatin analogs in the combined treatment of patients with hormone-resistant prostate cancer]	Kaprin AD et al.	Voprosy onkologii	2009	Clinical Trial
Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse	Choo R et al.	International journal of radiation oncology, biology, physics	2009	Clinical Trial, Phase II
Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis--a randomized, double-blind, multicenter, controlled trial	Harada T et al.	Fertility and sterility	2009	Randomized Controlled Trial
Antral follicle count at down-regulation and prediction of poor ovarian response	Khairy M et al.	Reproductive biomedicine online	2008	Clinical Trial
Successful treatment of unilateral cryptorchid boys risking infertility with LH-RH analogue	Hadziselimovic F	International braz j urol : official journal of the Brazilian Society of Urology	2008	Clinical Trial
Clinical outcome with half-dose depot triptorelin is the same as reduced-dose daily buserelin in a long protocol of controlled ovarian stimulation for ICSI/embryo transfer: a randomized double-blind clinical trial (NCT00461916)	Safdarian L et al.	Human reproduction (Oxford, England)	2007	Randomized Controlled Trial
Allopregnanolone decrease with symptom improvement during placebo and gonadotropin-releasing hormone agonist treatment in women with severe premenstrual syndrome	Nyberg S et al.	Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology	2007	Randomized Controlled Trial
Dynamics of pituitary down-regulation and ovarian response to controlled stimulation in in vitro fertilization cycles	Mohamed KA et al.	Fertility and sterility	2007	Controlled Clinical Trial
Efficacy of low-dose human chorionic gonadotropin (hCG) in a GnRH antagonist protocol	Koichi K et al.	Journal of assisted reproduction and genetics	2006	Randomized Controlled Trial
Comparison of outcome of clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol and buserelin long protocol--a randomized study	Lin YH et al.	Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology	2006	Randomized Controlled Trial
Duration of testosterone suppression after a [amount hidden] implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study	Pettersson B et al.	European urology	2006	Clinical Trial

More cited research

Conditions researched

Related compounds

FAQ

How many registered human trials study Buserelin?

The PeptideWhiz trial index lists 24 registered trials for Buserelin, the most recent from 2021.

How much published research exists on Buserelin?

The PeptideWhiz paper index links 387 PubMed papers to Buserelin; by study type, 421 human and 27 animal studies.

Which conditions is Buserelin researched for?

Anemia, Endometriosis, Female fertility, Male fertility and sperm, Osteoporosis and bone density, PCOS, PMDD (premenstrual dysphoric disorder), Post-surgical inflammation and surgery recovery, Pregnancy and breastfeeding: safety notes, Prostate inflammation.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research